ACHN
Achillion Pharmaceuticals, Inc.
ACHN
ACHN
Delisted
ACHN was delisted on the 27th of January, 2020.
127 hedge funds and large institutions have $415M invested in Achillion Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 38 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
127
Holders Change
-22
Holders Change %
-14.77%
% of All Funds
2.91%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
17
Increased
41
Reduced
38
Closed
36
Calls
$3.12M
Puts
$259K
Net Calls
+$2.87M
Net Calls Change
+$2.5M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.3M |
| 2 |
AC
Armistice Capital
New York
|
+$15.9M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.7M |
| 4 |
Goldman Sachs
New York
|
+$9.98M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.94M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$23.5M |
| 2 |
Morgan Stanley
New York
|
-$16.7M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$7.42M |
| 4 |
Renaissance Technologies
New York
|
-$4.85M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$4.63M |
